Waters Corp (WAT) company profile
Close on Nov 17, 2026Market cap $44.19BP/E 112.2Yield –
About Waters
Laboratory Analytical Instruments, SIC 3826
Waters Corporation designs, develops, manufactures, distributes, and services analytical instruments, software platforms, and laboratory consumables. Its core technologies encompass liquid chromatography, mass spectrometry, thermal analysis, rheometry, and calorimetry systems, alongside chromatography columns, specialized sample preparation products, and comprehensive post-warranty maintenance services. With the addition of diagnostic and bioscience solutions, the company organizes its operations across four principal segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. Its solutions primarily serve customers in the pharmaceutical and life sciences industries, while also supporting industrial manufacturers, environmental testing laboratories, nutritional safety facilities, clinical diagnostic centers, academic institutions, and government agencies.
The enterprise conducts operations on an international scale, distributing products and providing technical support through 82 sales offices situated around the world. Its global commercial outreach is supported by approximately 4,300 field representatives who directly handle customer accounts, instrument installations, training, and maintenance. Waters maintains manufacturing, testing, and machining capabilities at its facility in Milford, Massachusetts.
Summary of the business section of Waters's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Waters Corp
- Founded
- 1991
- Headquarters
- Milford, MA
- Address
- 34 Maple St 01757
- Phone
- (508) 478-2000
- Website
- www.waters.com
- Employees
- 7,600, Dec 31, 2024
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- WAT
- Exchange
- NYSE
- IPO date
- Nov 17, 1995
- Shares outstanding
- 98M, Aug 7, 2026
- Public float
- $20.97B, Jun 28, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Aug 28, 2000; 2-for-1, Jun 11, 1999
- SEC CIK
- 1000697
- CUSIP
- 941848103
- ISIN
- US9418481035
- FIGI
- BBG000FQRVM3
- Share class FIGI
- BBG001S8MDG9
- LEI
- 5T547R1474YC9HOD8Q74
- EIN
- 13-3668640
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Udit Batra | President and CEO, Director | 33,140 |
| Tong (NMN) Wu | SVP Waters Analytical Sciences | 1,081 |
| D. Steven Conly | SVP, Waters Biosciences | 6,030 |
| Robert L. Carpio III | SVP Waters Analytical Sciences | 3,426 |
| Amol Chaubal | SVP & Chief Financial Officer | 7,835 |
| Jianqing Bennett | SVP Waters Adv. Diagnostics | 6,532 |
| Heather Knight | Director | 1,338 |
| Wei Jiang | Director | 3,630 |
| Christopher A. Kuebler | Director | 17,808 |
| Richard H. Fearon | Director | 3,302 |
| Linda Baddour | Director | 2,899 |
| Claire Fraser | Director | 489 |
| Pearl S. Huang | Director | 3,276 |
| Flemming Ornskov | Director | 5,271 |
| Daniel J. Brennan | Director | 1,355 |
| Mark Vergnano | Director | 4,540 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $13.97M | $10.65M | $3.21M | $154 | $69 |
| FY2024 | $11.15M | $14.56M | $2.53M | $150 | $72 |
| FY2023 | $8.74M | -$1.12M | $2.34M | $133 | $76 |
| FY2022 | $9.41M | $10.83M | $2.69M | $138 | $86 |
| FY2021 | $8.65M | $19.06M | $2.44M | $151 | $127 |
| FY2020 | $5.71M | $6.98M | $1.92M | $106 | $129 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Udit Batra President & CEO | $1.15M | $7.43M | $3.00M | $2.37M | $21.00K | $13.97M | +25% |
| Amol Chaubal SVP & CFO | $650.00K | $1.73M | $689.95K | $750.75K | $21.00K | $3.84M | +23% |
| Jianqing Y. Bennett SVP, TA & Clinical Division | $633.00K | $1.28M | $509.86K | $522.23K | $21.00K | $2.97M | +19% |
| Robert Carpio III SVP, Waters Division | $600.00K | $1.13M | $449.99K | $618.75K | $21.00K | $2.82M | +45% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“With approximately 7,600 employees worldwide, Waters operates directly in over 35 countries and has products available in more than 100 countries.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 9, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 12, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 16, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 24, 2013 | Deregistration | Termination of SEC registration (Form 15) |
| Apr 9, 2013 | Delisting | Notice of delisting from exchange (Form 25) |
| Mar 31, 2006 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
See a number that looks wrong?